Dashboard
Manage Tickers

ARQT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/28/2025 17:06:24

crude-oil-falls-over-2-paypal-shares-spike-higher
Crude Oil Falls Over 2%; PayPal Shares Spi...
10/28/2025 16:18:17

wayfair-qorvo-celestica-united-parcel-service-regeneron-pharmaceuticals-and-other-big-stocks-moving-higher-on-tuesday
Wayfair, Qorvo, Celestica, United Parcel S...
10/28/2025 14:14:02

arcutis-biotherapeutics-q3-eps-006-beats-010-estimate-sales-99219m-beat-86978m-estimate
Arcutis Biotherapeutics Q3 EPS $0.06 Beats...
10/28/2025 12:31:21

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate ...

earnings-scheduled-for-october-28-2025
Earnings Scheduled For October 28, 2025
10/28/2025 11:11:34

uncovering-potential-arcutis-biotherapeuticss-earnings-preview
Uncovering Potential: Arcutis Biotherapeut...
10/27/2025 19:01:24

arcutis-to-present-zoryve-data-at-2025-fall-clinical-dermatology-conference-oct-23-26
Arcutis To Present ZORYVE Data At 2025 Fal...
10/24/2025 12:01:14

fda-approves-arcutis-zoryve-cream-005-for-atopic-dermatitis-in-children-between-2-to-5
FDA Approves Arcutis' ZORYVE Cream 0.05% F...
10/06/2025 12:16:07

arcutis-to-present-new-zoryve-foam-cream-data-at-european-academy-of-dermatology-and-venereology-congress-in-paris
Arcutis To Present New ZORYVE Foam Cream D...
09/17/2025 08:38:25

arcutis-submits-snda-to-expand-zoryve-cream-use-for-plaque-psoriasis-in-children-as-young-as-2
Arcutis Submits sNDA To Expand ZORYVE Crea...
09/03/2025 15:47:15

If approved, ZORYVE cream would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as youn...

top-5-biotech-stocks-with-strong-momentum
Top 5 Biotech Stocks With Strong Momentum
08/28/2025 11:19:00

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-22
Needham Maintains Buy on Arcutis Biotherap...
08/07/2025 10:34:01

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

arcutis-biotherapeutics-q2-eps-013-beats-017-estimate-sales-81504m-beat-72753m-estimate
Arcutis Biotherapeutics Q2 EPS $(0.13) Bea...
08/06/2025 20:01:25

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

this-palantir-technologies-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This Palantir Technologies Analyst Begins ...
07/25/2025 12:34:15

goldman-sachs-initiates-coverage-on-arcutis-biotherapeutics-with-neutral-rating-announces-price-target-of-18
Goldman Sachs Initiates Coverage On Arcuti...
07/25/2025 10:59:53

Goldman Sachs analyst Richard Law initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral rating and ann...

arcutis-biotherapeutics-zoryve-cream-015-received-recommendation-in-focused-guideline-update-for-management-of-adult-ad-from-aad
Arcutis Biotherapeutics' ZORYVE cream 0.15...
06/26/2025 12:08:55

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.1...

arcutis-biotherapeutics-enrolls-first-child-in-phase-2-open-label-study-integument-infant-evaluating-safety-and-tolerability-of-investigational-zoryve-cream-005-in-infants-with-ad-applied-once-daily-over-a-four-week-period
Arcutis Biotherapeutics Enrolls First Chil...
06/10/2025 12:14:09

Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 year...

arcutis-unveils-long-term-efficacy-safety-for-zoryve-cream-in-pediatric-patients-with-atopic-dermatitis
Arcutis Unveils Long-Term Efficacy, Safety...
06/06/2025 15:11:50

Arcutis will present five posters at RAD 2025 featuring long-term safety and efficacy data for Zoryve cream in children with ec...

arcutis-says-new-data-from-phase-3-integument-ole-long-term-open-label-study-show-durable-improvement-in-signs-and-symptoms-of-atopic-dermatitis
Arcutis Says New Data From Phase 3 INTEGUM...
06/06/2025 12:03:35

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION